Hi Guys, Congratulations on your success. We are an early-stage venture fund (d3vc.ai) that invests in select RegCF offerings that our algorithm selects. You scored high and we discussed your offering during our last investment committee meeting. We have the following questions we were hoping you could answer for us: 1. Reimbursement reality check: At $995 out-of-pocket, what % of osteopenia patients would actually buy this? Is this a "nice to have" or would patients pay cash for it? 2. CT vs DEXA: You used CT in trials but DEXA is the insurance/clinical standard. Do you have any plans to do any DEXA studies? 3. Time to fracture data: Realistically, how many years would a fracture reduction study take? Is this a 3-year or 10-year timeline? 4. Prescribing behavior: If FDA-cleared and a patient asks about it, would doctors prescribe/recommend it today without fracture data? Or would they wait? 5. Competitive landscape: Are there any other non-pharma devices in this space? 6. NASA angle: Do you have any visibility into whether NASA has tracked fracture outcomes in astronauts using vibration therapy? This could be low-cost validation data if it exists. Thanks, Sherwood Neiss, D3VC

Osteoboost Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Only FDA-cleared non-drug treatment for osteopenia – 47M Americans need this.

$2M in sales in 5 months – with zero ad spend. (Includes preorders)

14,000-person waitlist before launch – all organic word-of-mouth.

83-85% reduction in bone loss – NASA-funded, FDA-validated clinical results.

1,700+ doctors prescribing – from Harvard, Stanford, Mayo Clinic, UCSF.

2,800+ prescriptions in 5 months – 17% of doctors writing repeats.

70% profit margins from day one – every patient profitable at $995.

$100B+ global market – starting with $21B US osteopenia market.